Vascular risk factors aggravate the progression of Alzheimer's disease: A 3-year follow-up study of Chinese population

American Journal of Alzheimer's Disease and other Dementias

Volumn 29, Issue 6, 2014, Pages 521-525

  Qiao, Jin ^a   Lu, Wen Hui ^a   Wang, Jin ^a   Guo, Xiao Juan ^a   Qu, Qiu Min ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Cognition; Progression; Vascular risk factors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; ORAL ANTIDIABETIC AGENT;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHINESE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; ASIAN CONTINENTAL ANCESTRY GROUP; COMPLICATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; RISK FACTOR; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS;

EID: 84927709658     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317514522853     Document Type: Article

References (37)

1. Fratiglioni L, Launer L, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology. 1999;54(11 suppl 5):S10-S15.
2. Dickstein DL, Walsh J, Brautigam H, Stockton SD, Gandy S, Hof PR. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med. 2010;77(1):82-102.
3. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67(6):505-512.
4. Helzner EP, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol. 2009;66(3):343-348.
5. Mielke M, Rosenberg P, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology. 2007; 69(19):1850-1858.
6. MusiccoM, Palmer K, Salamone G, et al. Predictors of progression of cognitive decline in Alzheimer's disease: the role of vascular and sociodemographic factors. J Neurol. 2009;256(8):1288-1295.
7. Regan C, Katona C, Walker Z, Hooper J, Donovan J, Livingston G. Relationship of vascular risk to the progression of Alzheimer disease. Neurology. 2006;67(8):1357-1362.
8. Sanz C, Andrieu S, Sinclair A, Hanaire H, Vellas B. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology. 2009;73(17):1359-1366.
9. Zhang ZX, Zahner GE, Román GC, et al. Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch Neurol. 2005;62(3):447-453.
10. Zhou DH, Wang JY, Li J, Deng J, Gao C, Chen Me. Study on frequency and predictors of dementia after ischemic stroke. J Neurol. 2004;251(4):421-427.
11. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10(9): 819-828.
12. Roselli F, Tartaglione B, Federico F, Lepore V, Defazio G, Livrea P. Rate of MMSE score change in Alzheimer's disease: influence of education and vascular risk factors. Clin Neurol Neurosurg. 2009;111(4):327-330.
13. Stern Y, Albert S, Tang M-X, Tsai W-Y. Rate of memory decline in AD is related to education and occupation cognitive reserve? Neurology. 1999;53(9):1942-1947.
14. Storandt M, Grant EA, Miller JP, Morris JC. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology. 2002;59(7):1034-1041.
15. Andel R, Vigen C, Mack WJ, Clark LJ, Gatz M. The effect of education and occupational complexity on rate of cognitive decline in Alzheimer's patients. J Int Neuropsychol Soc. 2006;12(1):147-152.
16. De la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004;3(3):184-190.
17. Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev. 2002;1(1): 61-77.
18. Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio F. Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data. J Neurol Sci. 2002;203:147-51.
19. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. JAMA. 1995;274(23):1846-1851.
20. Abellan van Kan G, Rolland Y, Nourhashémi F, Coley N, Andrieu S, Vellas B. Cardiovascular disease risk factors and progression of Alzheimer's disease. Dementia Geriatr Cogn Disord. 2009;27(3): 240-246.
21. Arntzen K, Schirmer H, Wilsgaard T, Mathiesen E. Impact of cardiovascular risk factors on cognitive function: the Tromsø study. Eur J Neurol. 2011;18(5):737-743.
22. Cechetto DF, Hachinski V, Whitehead SN. Vascular risk factors and Alzheimer's disease. Exp Rev Neurother. 2008;8(5):743-750.
23. Duron E, Hanon O. Hypertension, cognitive decline and dementia. Arch Cardiovasc Dis. 2008;101(3):181-189.
24. Kalback W, Esh C, Castaño EM, et al. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res. 2004;26(5):525-539.
25. Van Dijk EJ, Breteler MM, Schmidt R, et al. The association between blood pressure, hypertension, and cerebral white matter lesions cardiovascular determinants of dementia study. Hypertension. 2004;44(5):625-630.
26. Gentile MT, Poulet R, Pardo AD, et al. b-Amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging. 2009;30(2):222-228.
27. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulinlike growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63-80.
28. Ott A, Stolk R, Van Harskamp F, Pols H, Hofman A, Breteler M. Diabetes mellitus and the risk of dementia the Rotterdam study. Neurology. 1999;53(9):1937-1942.
29. Escribano L, Simón AM, Gimeno E, et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacol. 2010;35(7):1593-604.
30. Risner M, Saunders A, Altman J, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006;6(4):246-254.
31. Lesort M, Johnson G. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience. 2000;99(2):305-316.
32. Isobe C, Murata T, Sato C, Terayama Y. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci. 2005; 77(15):1836-1843.
33. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346(7):476-483.
34. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cellul Neurosci. 2005; 28(1):195-204.
35. Pacheco Quinto J, Rodriguez de Turco EB, DeRosa S, et al. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid b peptide levels. Neurobiol Dis. 2006;22(3):651-656.
36. Jellinger KA. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol. 2007;113(4):349-388.
37. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12(12):723-738.